Abstract: The present invention relates to a mupirocin topical pharmaceutical composition in a pump device, and its use for dispensing predetermined quantities of mupirocin for treating skin lesions.

Abstract: The invention is directed to topical drug vehicle platform compositions for ophthalmological and dermatological use. These compositions comprise a means to sequester tears and an ophthalmological drug. The invention is further directed to methods of treating a spectrum of ocular surface disease epitheliopathies including but not limited to dry eye in a human or mammal. The invention is further directed to contact lenses, punctum plugs, pellets or any other device used to deliver drugs to the surface of the eye, coated or infused with compositions of the invention.

Abstract: Methods and compositions are provided for treating a patient having a bleeding disorder during or after a dental procedure to reduce bleeding or need for factor replacement therapy. Aqueous pharmaceutical compositions are provided comprising tranexamic acid, sodium carboxymethyl cellulose, Tween® 20, and menthol wherein the composition exhibits good long term stability, little to no discoloration over time, and reduced bitterness compared to a control solution of tranexamic acid and water.

Abstract: A composition comprising an aqueous suspension comprising an incretin mimetic and an organic acid is described. The organic acid is one that (i) has a water solubility at room temperature of between about 0.01 and 10 g/L, (ii) has a molar mass of less than about 500 grams per mole, and/or (iii) maintains a pH of the suspension in its environment of use of between 3.0-6.0 for a period of at least about 30 days, and stabilizes the incretin mimetic to provide a composition that is suitable for delivering the compound in a biologically active or potent form for a sustained period of time. Devices comprising the compositions and methods of treatment are also described.

Abstract: The invention provides liquid compositions in the form of physically stable emulsions comprising a semifluorinated alkane. The semifluorinated alkane is comprised in the dispersed phase, which may also include an active pharmaceutical ingredient. One of the preferred active ingredients is propofol. The compositions are optionally heat sterilisable and can be used for pharmaceutical or cosmetic product applications, and administered topically, intravenously, or via other routes.

Abstract: Methods of decreasing, in a human or other animal, the susceptibility of atherogenic particles to aggregation induced by sphingomyelinase, the methods comprising administering vesicles to the animal. Also similar methods directed at the formation of cholesterol crystals, abnormal cholesterol enrichment of cell membranes, and denaturation of Apo B.

Abstract: Compositions comprising liposomes composed of whole cell membrane fraction are provided. The liposomes may be attached to, or encapsulate a pharmaceutical agent. Also provided are methods of generating and using these liposomes.

Abstract: Microspheres comprising a core material, wherein the microspheres have a circularity greater than 0.95 and an aspect ratio greater than 0.95, and methods of manufacturing the same. The microspheres may be useful in the manufacture of sustained and modified release active pharmaceutical ingredient (API) microspheres, as a free flowing excipient for mini-tablets and in the manufacture of API dispersions.

Abstract: The invention provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.

Abstract: The present invention relates to a process for preparing hypromellose hard capsule using thermogelation with improved storage stability, film strength, film distribution, filling up performance and/or bioavailability of ingredient. More specifically, this invention relates to a process for preparing hypromellose hard capsule using thermogelation with improved storage stability, film strength, film distribution, filling up performance and/or bioavailability of ingredient, comprising the steps of: i) sequentially adding and solubilizing 0.1-0.5 wt part of plasticizer, 0.1-0.5 wt part of wetting agent and a small amount of a viscosity stabilizer to the 100 wt part of hypromellose aqueous dispersion containing 19-22 wt part of hypromellose; ii) adjusting the viscosity of the mixture into 800-1,300 cP; iii) dipping the mold pin into the hypromellose aqueous solution maintained at 19-21° C. after preheating the mold pin to be 100-120° C.; and iv) forming the hypromellose hard capsule.

Abstract: The present invention relates to gelatin capsules containing microbeads. The capsule has perforations that enhance the dissolution of the capsule.

Abstract: Disclosed is a prolonged release pharmaceutical dosage form comprising a plurality of coated beads, each comprising a granule, a first layer coated on the granule comprising hydromorphone, naloxone, an antioxidant compound and a chelatmg compound; and a second layer coated on the first layer comprising a prolonged release agent. The dosage form has improved stability and dissolution properties. Also disclosed is the use of a combination of an antioxidant, such as sodium metabisulfite, and a chelatmg agent, such as EDTA, to improve the stability and/or dissolution properties of a prolonged release dosage form comprising hydromorphone and naloxone.

Abstract: Compositions for reducing the frequency of urination and methods of manufacture of the compositions are disclosed. One method of manufacture include the steps of forming a first mixture comprising a first active ingredient comprising one or more analgesic, coating the first mixture with a first delayed-release coating to form a first component, forming a second mixture comprising a second active ingredient comprising one or more analgesic agents, coating the second mixture with a second delayed-release coating to form a second component, and combining the first component with the second component to form a third mixture.

Abstract: Compositions and methods are disclosed herein to deliver and anchor nanoscale drug carriers into the extracellular matrix (ECM) of tissues, such as degenerating cartilage or tumor margins, and to provide local and sustained release of drugs.

Abstract: The invention relates to medical treatment patch, ideally for applying topically, that permits the targeted, sustained and controlled release of potassium KMnO4; and a method of treating a skin disorder comprising applying said patch.

Abstract: There is provided a wound dressing prepared with a hydrocolloid gel, a polyurethane film, a PVA hydrogel, an alginate gel or the like, which has excellent stretchability and exudation absorbency of the wound surface for protection and prevention of infection on the wound surface in which continuity of a body tissue is destroyed by a physical impact or the like, can maintain a wet environment suitable for promoting healing of the wound surface, and has no pain or no worry to damage regenerated skin when the wound dressing is exchanged.

Abstract: Subject of the present invention are assays and in vitro methods for the in vitro diagnosis, prognosis and risk stratification of a patient having a primary, non-infectious disease, whereby the level of Procalcitonin (PCT) in a sample of a body fluid of the patient is indicative for the risk of the patient to contract a further disease or medical condition.

Abstract: The invention provides artificial tear compositions comprising a means for inducing tears and a means for sequestering tears. The invention further provides methods for treating dry eye, ocular surface defects, deficiencies or diseases, eye pain and Meibomian gland dysfunction.

Abstract: A method for treat acne comprising administering between 50 mg and 3000 mg of a topical liquid or gel composition comprising between 1% w/w and 15% w/w cannabinoid, wherein the cannabinoid is dissolved in the liquid or gel composition is described.

Abstract: Systems and methods provide sugar alcohol to heat stressed ruminants to improve performance. During periods of high temperature or humidity, heat stressed ruminants may exhibit decreased dry matter intake, and in response, an effective amount of sugar alcohol such as sorbitol may be provided in the ruminant diet to cause performance to increase, which may include increased milk yield, improved feed efficiency or both compared to heat stressed dairy cattle without sugar alcohol in the diet.

Abstract: Disclosed are nanoparticle compositions comprising nanoparticles prepared from denatured, cross-linked albumin and a therapeutic agent for treating a neutrophil-mediated inflammation, and methods of treating neutrophil-mediated inflammation using the compositions.

Abstract: The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydrocannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably, the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts.

Abstract: The invention relates to pharmaceutical compositions comprising a statin and a cannabinoid, and their use for the treatment of hypercholesterolemia and atherosclerosis. It has been found that compositions combining a statin and a cannabinoid are improved over existing statin formulations. The compositions of the invention for example allow for a lower effective dose of statin and a reduction of the adverse effects seen with statins taken alone. Dosing ranges and formulations suitable for oral, buccal, and sublingual administration are disclosed. Various specific cannabinoids such as cannabidiol and synthetic cannabidiols selected for their anti-inflammatory, antioxidant, and anti-atherosclerotic effect are shown to be particularly advantageous.

Abstract: A cannabis-based therapeutic product for treatment of chronic pain produced by separating hash resin from plant material of the cannabis plant, pressing the hash resin to expel oil, leaving spent hash resin, extracting further cannabinoids from the spent hash resin using MCT oil, separating the cannabis compounds from the oils using high pressure liquid chromatography, flash chromatography, or similar techniques, and processing selected cannabis compound formulations into a form suitable for administration as a therapeutic product for treatment of chronic pain. The therapeutic product has at least 28% w/w cannabinol (CBD), and at least 2% w/w ?-myrcene.

Abstract: The present application relates to a method of treating Parkinson's disease by administering a mouth-dissolving composition of N-propargylamine derivative, such as rasagiline or a pharmaceutically-acceptable salt thereof.

Abstract: Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.

Abstract: Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.

Abstract: The present invention includes compositions for treating a lysosomal storage disease or disorder, and methods using same. In certain embodiments, the compositions of the invention comprise a histone deacetylase inhibitor (HDACi), a cyclodextrin, water, optionally a polyalkylene glycol, and optionally dimethyl sulfoxide (DMSO). In other embodiments, the compositions of the invention comprise a HDACi, a cyclodextrin, water, a polyalkylene glycol, and DMSO.

Abstract: The invention relates CETP modulator which is useful in the prevention, treatment, delaying progression and/or reduction of eye diseases.

Abstract: Embodiments herein disclose methods relating to diabetic nephropathy (DN); methods for preventing the onset and also for preventing the progressing of DN, as well as the treatment of DN in diabetic subjects comprising administering reparixin and/or ladarixin which are inhibitors of CXCL8 receptor CXCR1 and CXCR2 activation.

Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.

Abstract: Described herein are methods of reducing the risk of recurrence of bacterial vaginosis by intravaginal administration of compositions comprising L-lactic acid, polymer thickener, and preservative.

Abstract: Compositions for neuroprotection and treatment of neurodegeneration and methods of administering same. In particular, the present invention relates to compositions and methods for preventing or reducing neurodegeneration, such as neurodegeneration caused by Huntington's disease, including administering a daily dose of a composition including an effective amount of creatine hydrochloride to a patient in need thereof. The methods of the present invention allow for lower dosages of supplementation as compared to creatine monohydrate while retaining all of the desired biological effects of creatine supplementation.

Abstract: Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.

Abstract: The present invention describes a new method and new combination products for the therapy of neurological and other conditions which respond to dopaminergic therapies and especially to L-DOPA (L-Dihydroxy-Phenylalanine) based on the use of L-DOPA esters, especially of L-DOPA glycerol ester and L-DOPA Cholin Ester.

Abstract: The present invention relates to the compositions comprising 15-HEPE and methods of treatment relating to same.

Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.

Abstract: The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions. In certain embodiments, the invention provides a method of treating an overweight or obese subject including administering a MetAP2 inhibitor in which the amount administered does not substantially modulate angiogenesis.

Abstract: Methods of treating cancer using and kits comprising at least one gemcitabine, at least one nab-paclitaxel, and at least one compound of formula (I)

Abstract: The invention relates to an antimicrobial composition of monoanhydro-hexitol monoalkyl ether isomers bearing an alkyl ether radical (OR) at C-3, C-5 or C-6 of the monoanhydro-hexitol, in which the alkyl group (R) is a linear or branched, cyclic or noncyclic hydrocarbon-based group comprising between 4 to 18 carbon atoms. The invention also relates to a method for disinfecting a surface and/or equipment contaminated by bacteria, said method comprising applying to said surface or equipment to be disinfected, a composition according to the invention.

Abstract: The present disclosure provides nitroxyl donating pharmaceutical compositions comprising N-substituted hydroxylamine derivatives. The compositions are highly efficacious in treating cardiovascular diseases (e.g., heart failure), have a suitable toxicological profile, and are sufficiently stable for intravenous or oral administration.

Abstract: A composition for facilitating eyelash and/or eyebrow growth which includes at least forskolin derived exclusively from coleus forskohlii and at least one keratmocyte growth stimulator. In some embodiments, the keratinocyte growth stimulator may be at least one plant extract, wherein the at least one plant extract is selected from a group comprising: tussilago farfara flower extract, achillea millefolium extract, cinchona succirubra bark extract, nasturtium officinale, tropaeolum majus. The composition may also comprise a lipid phase, comprising castor oil.

Abstract: The disclosure provides a method of treating pulmonary fibrosis, including idiopathic pulmonary fibrosis, in a comprising administering to the subject a pharmaceutical composition comprising from about 1% by weight to about 99% by weight of cromolyn sodium with an inhalation device.

Abstract: The disclosure provides a method of treating pulmonary fibrosis, including idiopathic pulmonary fibrosis, in a comprising administering to the subject a pharmaceutical composition comprising from about 1% by weight to about 99% by weight of cromolyn sodium with an inhalation device.

Abstract: The present application concerns compositions comprising ellagitannins and proanthocyanidins, and the use of such compositions for preventing or treating endothelial dysfunction. The compositions of the invention comprise at least one ellagitannin in combination with at least one proanthocyanidin. The present application also concerns methods of treating, preventing, or delaying the onset of endothelial dysfunction using compositions comprising ellagitannins and proanthocyanidins.

Abstract: Methods and compositions for treating chronic obstructive pulmonary disease (COPD) and other obstructive diseases of the respiratory tract by administering soft anticholinergic esters once or twice daily with fewer systemic side-effects than glycopyrrolate.

Abstract: It is to provide an agent for preventing or improving hearing loss, which comprises a low molecular compound which can be produced relatively easily and inexpensively as an active ingredient. One or more compounds selected from the group consisting of compounds represented by the following formulas (I0), (II), and (III) and a pharmaceutically acceptable salt of the compounds when R3 is OH are used as an agent for preventing or improving hearing loss.

Abstract: Compositions of indoleamine 2,3-dioxygenase (“IDO”) inhibitors and methods of use thereof are provided. The disclosed compositions may be used to inhibit or reduce kynurenine production in the blood, treat or prevent muscle loss, increase or maintain muscle mass, muscle strength and/or muscle function, and treat or prevent sarcopenia.

Abstract: Calixpyrrole-based antitumor compounds are described, which can be derivatized to obtain their passive transport on tumor masses through the Enhanced Permeation and Retention, EPR, effect of the neoplastic vasculature. The conjugation of the above mentioned compounds with peptides/antibodies is further described, for their possible active transport on tumor cells.

Abstract: The present invention relates to a pharmaceutical cream, cream-gel, or gel composition comprising benzydamine having improved tolerability and efficacy for the prevention and treatment of inflammatory and/or infective conditions mainly localized in the genital area, in particular vaginosis, vaginitis and vulvo-vaginitis.